UCB
FDA rejects UCB’s psoriasis therapy bimekizumab
Phil Taylor
bimekizumab, fda, psoriasis, regulatory, UCB
0 Comment
Patients/ Views & Analysis/ Views and analysis
Engagement to partnership: The changing face of patient involvement
Amanda Barrell
Iris Loew-Friedrich, patient engagement, UCB
0 Comment
NICE ends UK access disparity to osteoporosis drug Evenity
Phil Taylor
Amgen, Evenity, HEOR, NHS, osteoporosis, UCB
0 Comment
UCB preps filings for another challenger to AZ’s Soliris
Phil Taylor
Apellis Pharma, Argenx, AstraZeneca, myasthenia gravis, rozanolixizumab, Soliris, UCB, Ultomiris, zilucoplan
0 Comment
UCB chases after Argenx with FcRN drug for myasthenia gravis
Phil Taylor
Argenx, autoimmune disease, efgartigimod, myasthenia gravis, rozanolixizumab, UCB
0 Comment
Novartis takes aim at risky Parkinson’s target with $1.5bn UCB deal
Phil Taylor
neurology, Novartis, Parkinson's disease, partnering, UCB
0 Comment
Pharma group will develop ‘digital endpoint’ for atopic dermatitis
Phil Taylor
AbbVie, atopic dermatitis, clinical trials, digital, digital endpoint, digital health, Janssen, Novartis, Pfizer, UCB
0 Comment
UCB licenses AI tech for spinal fracture detection to ImageBiopsy
Phil Taylor
bone, diagnostic, digital, digital health, ImageBiopsy Lab, osteoporosis, UCB
0 Comment